[Low-dose hormonal therapy during climacteric]

Abstract

Long time ago hormone therapy has had several indications during climacteric. However, after WHI study, its use has been reconsidered. According to several current consensus, hormone therapy must be prescribed to control vasomotor symptoms; low-doses are associated with lower risks than conventional doses. Multiple studies report benefits of low-dose and ultra low-dose of hormone therapy during climacteric. Here we review the literature on low and ultra low hormone therapy doses used in climacteric women, an alternative that must be considered a baseline indication for climacteric symptomatic women.